RNAAvidity Biosciences, Inc.

Nasdaq aviditybiosciences.com


$ 46.96 $ 5.08 (12.13 %)    

Friday, 09-Aug-2024 15:59:56 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 46.95
$ 46.90 x 100
-- x --
-- - --
$ 4.83 - $ 48.80
2,485,896
na
5.02B
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 02-28-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 02-28-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-avidity-biosciences-raises-price-target-to-60

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $4...

 avidity-biosciences-q2-eps-065-beats-079-estimate-collaboration-revenue-204m-miss-264m-estimate

Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(...

 avidity-biosciences-says-data-suggest-del-zota-has-potential-to-change-treatment-paradigm-and-course-of-disease-for-patients-with-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping

AOC 1044 demonstrated favorable safety and tolerability. Avidity also announced delpacibart zotadirsen as the approved internat...

 genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

 genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

 top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

 avidity-biosciences-and-cleanspark-were-among-the-10-biggest-mid-cap-stock-gainers-last-week-june-9-june-15-are-these-in-your-portfolio

Top mid-cap performers: Avidity Biosciences, Iris Energy, Hims & Hers Health, John Wiley & Sons, Element Solutions, Cle...

 reported-earlier-avidity-biosciences-prices-4009m-public-offering-of-1055m-common-shares-at-38share

All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before...

 b-of-a-securities-maintains-buy-on-avidity-biosciences-raises-price-target-to-45

B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target fr...

 needham-maintains-buy-on-avidity-biosciences-raises-price-target-to-46

Needham analyst Joseph Stringer maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $35 t...

 chardan-capital-maintains-buy-on-avidity-biosciences-raises-price-target-to-45

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $3...

 evercore-isi-group-maintains-outperform-on-avidity-biosciences-raises-price-target-to-45

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION